Swedish human care company Elekta has unveiled new Leksell Vantage stereotactic system for use in neurosurgery procedures.

The system has been developed to address the limitations of using metal components during stereotactic MR and CT imaging.

It features new stereotactic arc, a surgical positioning device that enables to prepare the sterile field.

It helps to set target coordinates between the left and the right brain hemisphere in deep brain stimulation (DBS) lead placements.

Featuring lightweight and open face design, the system reduces the risk of device-related skin sensations due to temperature increase during MR scans.

Stereotactic neurosurgery will be used for DBS implantations, brain biopsies and drug deliveries to delicate brain targets, as well as cranial radiosurgery.

Leksell Vantage stereotactic system, which is not yet CE marked or FDA 510(k) cleared, is not available for sale or distribution.

The company plans to commercialize the system for clinical use in Europe during 2017.

The company is showcasing the new system at the European Society for Stereotactic and Functional Neurosurgery (ESSFN) meeting in Madrid, which is being held from 28 September to 1 October.

Elekta treatment management portfolio senior vice president Dee Mathieson said: “Building on our heritage and the invention of Lars Leksell, Elekta’s founder, our current Leksell Stereotactic Systems have been employed in more than 1,500 centers worldwide.

“We expect the benefits of Leksell Vantage to make our system even more competitive as it allows for faster stereotactic neuroimaging without compromise, and with fewer components it results in a smoother workflow.”